{
    "root": "2f99c3b5-a213-50ae-e063-6394a90a5152",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "NovoLog Mix 70/30",
    "value": "20250305",
    "ingredients": [
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, DIHYDRATE",
            "code": "94255I6E2T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37586"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "METACRESOL",
            "code": "GGO4Y809LO"
        },
        {
            "name": "PHENOL",
            "code": "339NCG44TV",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15882"
        },
        {
            "name": "PROTAMINE SULFATE",
            "code": "0DE9724IHC",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "ZINC",
            "code": "J41CSQ7QDS",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01593"
        },
        {
            "name": "INSULIN ASPART",
            "code": "D933668QVX",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_145810"
        }
    ],
    "indications": {
        "text": "novolog mix 70/30 mixture insulin aspart protamine insulin aspart indicated improve glycemic control adult patients diabetes mellitus . limitations : novolog mix 70/30 recommended treatment diabetic ketoacidosis . proportions rapid-acting long-acting insulins novolog mix 70/30 fixed allow basal versus prandial dose adjustments .",
        "doid_entities": [
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            },
            {
                "text": "diabetic ketoacidosis (DOID:1837)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1837"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "inspect visually . appearance uniformly white cloudy . looks clear contains solid particles ( 2.1 ) . novolog mix 70/30 must resuspended immediately . resuspension easier insulin reached room temperature ( 2.1 ) . inject novolog mix 70/30 subcutaneously abdominal region , buttocks , thigh , upper arm ( 2.1 ) . administer dose within 15 minutes meal initiation . patients type 2 diabetes , dose may also given meal initiation ( 2.1 ) . rotate injection sites within region one injection next reduce risk lipodystrophy localized cutaneous amyloidosis ( 2.1 ) . administer intravenously insulin infusion pumps ( 2.1 ) . novolog mix 70/30 typically dosed twice-daily ( dose intended cover 2 meals meal snack ) ( 2.2 ) . individualize based metabolic needs , blood glucose monitoring results , glycemic control goal ( 2.2 ) . adjustments may needed changes physical activity , changes meal patterns ( i.e . , macronutrient content timing food intake ) , changes renal hepatic function acute illness ( 2.2 ) . switching another insulin novolog mix 70/30 , different novolog mix 70/30 may needed ( 2.2 ) .",
        "doid_entities": [
            {
                "text": "type 2 diabetes (DOID:9352)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9352"
            },
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            },
            {
                "text": "lipodystrophy (DOID:811)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_811"
            },
            {
                "text": "amyloidosis (DOID:9120)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9120"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "novolog mix 70/30 ( insulin aspart protamine insulin aspart ) white cloudy injectable suspension containing 100 units/ml ( u-100 ) 70 % insulin aspart protamine 30 % insulin aspart available : novolog mix 70/30 flexpen dials 1-unit increments . ndc : 70518-2119-00 packaging : 5 1 carton , 3 ml 1 syringe plastic type 2 dispense original sealed carton enclosed instructions . store unused novolog mix 70/30 refrigerator 2\u00b0c 8\u00b0c ( 36\u00b0f 46\u00b0f ) . freeze novolog mix 70/30 novolog mix 70/30 frozen . expose novolog mix 70/30 excessive heat light . always remove needle injection store novolog mix 70/30 flexpen without needle attached . in-use ( unopened ) room temperature ( 30\u00b0c [ 86\u00b0f ] ) : 14 days in-use ( unopened ) refrigerated ( 2\u00b0c 8\u00b0c [ 36\u00b0f 46\u00b0f ] ) : expiration date in-use ( opened ) room temperature ( 30\u00b0c [ 86\u00b0f ] ) : 14 days ( refrigerate ) repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "novolog mix 70/30 contraindicated : episodes hypoglycemia [ ( 5.3 ) ] patients hypersensitivity novolog mix 70/30 one excipients [ ( 5.5 ) ]",
    "indications_original": "NOVOLOG MIX 70/30 is a mixture of insulin aspart protamine and insulin aspart indicated to improve glycemic control in adult patients with diabetes mellitus.\n                  \n                     Limitations of Use:\n                  \n                  \n                     NOVOLOG MIX 70/30 is not recommended for the treatment of diabetic ketoacidosis.\n                     The proportions of rapid-acting and long-acting insulins in NOVOLOG MIX 70/30 are fixed and do not allow for basal versus prandial dose adjustments.",
    "contraindications_original": "Inspect visually before use. Appearance should be uniformly white and cloudy. Do not use it if it looks clear or if it contains solid particles ( 2.1 ). NOVOLOG MIX 70/30 must be resuspended immediately before use. Resuspension is easier when the insulin has reached room temperature ( 2.1 ). Inject NOVOLOG MIX 70/30 subcutaneously in the abdominal region, buttocks, thigh, or upper arm (2.1). Administer the dose within 15 minutes before meal initiation. For patients with type 2 diabetes, the dose may also be given after meal initiation ( 2.1 ). Rotate injection sites within the same region from one injection to the next to reduce risk of lipodystrophy and localized cutaneous amyloidosis (2.1) . Do not administer intravenously or use in insulin infusion pumps ( 2.1 ). NOVOLOG MIX 70/30 is typically dosed twice-daily (with each dose intended to cover 2 meals or a meal and a snack) (2.2) . Individualize dosage based on metabolic needs, blood glucose monitoring results, glycemic control goal ( 2.2 ). Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness ( 2.2 ). When switching from another insulin to NOVOLOG MIX 70/30, a different dosage of NOVOLOG MIX 70/30 may be needed ( 2.2 ).",
    "warningsAndPrecautions_original": "NOVOLOG MIX 70/30 (insulin aspart protamine and insulin aspart) is a white and cloudy injectable suspension containing 100 units/mL (U-100) of 70% insulin aspart protamine and 30% insulin aspart available as:\n                  The NOVOLOG MIX 70/30 FlexPen dials in 1-unit increments.\n                  \n                  NDC: 70518-2119-00\n                  PACKAGING: 5 in 1 CARTON, 3 mL in 1 SYRINGE PLASTIC TYPE 2\n                  \n                  Dispense in the original sealed carton with the enclosed Instructions for Use. Store unused NOVOLOG MIX 70/30 in a refrigerator between 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F). Do not freeze NOVOLOG MIX 70/30 or use NOVOLOG MIX 70/30 if it has been frozen. Do not expose NOVOLOG MIX 70/30 to excessive heat or light.\n                  Always remove the needle after each injection and store NOVOLOG MIX 70/30 FlexPen without a needle attached.\n                  Not in-use (unopened) Room Temperature (up to 30\u00b0C [86\u00b0F]): 14 days\n                  Not in-use (unopened) Refrigerated (2\u00b0C to 8\u00b0C [36\u00b0F \u00a046\u00b0F]): until expiration date\n                  In-use (opened) Room Temperature (up to 30\u00b0C [86\u00b0F]): 14 days (Do not refrigerate)\n                  \n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "NOVOLOG MIX 70/30 is contraindicated:\n                  \n                     During episodes of hypoglycemia\n  \n   [\n   \n    see Warnings and Precautions (5.3)]\n  \n   \n                     \n                     In patients with hypersensitivity to NOVOLOG MIX 70/30 or one of its excipients\n  \n   \n                           [see Warnings and Precautions (5.5)]",
    "drug": [
        {
            "name": "NovoLog Mix 70/30",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37586"
        }
    ]
}